JP2016034978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016034978A5 JP2016034978A5 JP2015236260A JP2015236260A JP2016034978A5 JP 2016034978 A5 JP2016034978 A5 JP 2016034978A5 JP 2015236260 A JP2015236260 A JP 2015236260A JP 2015236260 A JP2015236260 A JP 2015236260A JP 2016034978 A5 JP2016034978 A5 JP 2016034978A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- eculizumab
- pnh
- treatment
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78307006P | 2006-03-15 | 2006-03-15 | |
| US60/783,070 | 2006-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013219882A Division JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017028811A Division JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016034978A JP2016034978A (ja) | 2016-03-17 |
| JP2016034978A5 true JP2016034978A5 (enExample) | 2016-09-23 |
| JP6224059B2 JP6224059B2 (ja) | 2017-11-01 |
Family
ID=38222520
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500498A Withdrawn JP2009530299A (ja) | 2006-03-15 | 2007-03-15 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2015236260A Active JP6224059B2 (ja) | 2006-03-15 | 2015-12-03 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500498A Withdrawn JP2009530299A (ja) | 2006-03-15 | 2007-03-15 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US20090220508A1 (enExample) |
| EP (5) | EP3124029A1 (enExample) |
| JP (9) | JP2009530299A (enExample) |
| KR (2) | KR20080110800A (enExample) |
| AU (1) | AU2007225044C1 (enExample) |
| BR (2) | BR122017024057B8 (enExample) |
| CA (2) | CA3022097C (enExample) |
| DK (1) | DK2359834T5 (enExample) |
| ES (2) | ES2965283T3 (enExample) |
| HU (2) | HUE066795T2 (enExample) |
| IL (4) | IL302157A (enExample) |
| MX (2) | MX340784B (enExample) |
| PL (2) | PL2359834T3 (enExample) |
| PT (1) | PT2359834T (enExample) |
| SI (1) | SI2359834T1 (enExample) |
| WO (1) | WO2007106585A1 (enExample) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
| IN2014DN10515A (enExample) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| PL2808343T3 (pl) * | 2007-12-26 | 2019-11-29 | Xencor Inc | Warianty Fc ze zmienionym wiązaniem do FcRn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| TWI700293B (zh) | 2008-04-11 | 2020-08-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗體 |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| HUE061548T2 (hu) * | 2008-11-10 | 2023-07-28 | Alexion Pharma Inc | Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények |
| CA2780153A1 (en) * | 2009-11-09 | 2011-05-12 | Alexion Pharmaceuticals, Inc. | Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| US20120213781A1 (en) | 2011-02-11 | 2012-08-23 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| PE20150159A1 (es) | 2011-12-21 | 2015-02-08 | Novartis Ag | Composiciones y metodos para anticuerpos que actuan sobre el factor p |
| EP3511339B1 (en) | 2012-02-20 | 2025-04-09 | IPC Research, LLC | Polypeptides binding to human complement c5 |
| HK1204693A1 (en) * | 2012-03-16 | 2015-11-27 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| US20160051673A1 (en) | 2013-03-29 | 2016-02-25 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| JP6767865B2 (ja) | 2013-08-28 | 2020-10-14 | スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） | ヒト補体ｃ５に結合する安定なポリペプチド |
| AU2014314214C1 (en) | 2013-08-28 | 2019-01-24 | Affibody Ab | Binding polypeptides having a mutated scaffold |
| US20150104445A1 (en) | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2895029T3 (es) | 2014-06-12 | 2022-02-17 | Ra Pharmaceuticals Inc | Modulación de actividad del complemento |
| EA201790342A1 (ru) | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| MX387238B (es) | 2014-09-29 | 2025-03-18 | Chemocentryx Inc | Procesos e compuestos intermedios en la preparación de antagonistas de c5ar. |
| WO2016061065A1 (en) | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of shifting an isoelectric profile of a protein product and uses thereof |
| TR201903267T4 (tr) | 2014-10-15 | 2019-03-21 | Alexion Pharma Inc | Büyük ölçekli eculizumab üretim hücre kültürünün replikasyon metotları. |
| US20160108357A1 (en) * | 2014-10-15 | 2016-04-21 | Alexion Pharmaceuticals, Inc. | Methods of culturing a cell |
| AU2015350075B2 (en) | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
| WO2016094834A2 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
| TWI656133B (zh) | 2014-12-19 | 2019-04-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法 |
| KR101838645B1 (ko) | 2014-12-19 | 2018-03-14 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
| JP2018511557A (ja) | 2015-01-22 | 2018-04-26 | 中外製薬株式会社 | ２種以上の抗ｃ５抗体の組み合わせおよび使用方法 |
| HUE056613T2 (hu) | 2015-01-28 | 2022-02-28 | Ra Pharmaceuticals Inc | Komplementaktivitás modulátorai |
| WO2016154290A1 (en) | 2015-03-23 | 2016-09-29 | Alexion Pharmaceuticals, Inc. | Virus filtration |
| US10556952B2 (en) | 2015-03-30 | 2020-02-11 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to Fc gamma receptors |
| JP6944375B2 (ja) * | 2015-03-31 | 2021-10-06 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置 |
| PH12017501834B1 (en) | 2015-04-06 | 2024-01-17 | Arcellx Inc | De novo binding domain containing polypeptides and uses thereof |
| HUE057432T2 (hu) | 2015-04-07 | 2022-05-28 | Alector Llc | Anti-sortilin antitestek és ezek alkalmazási módjai |
| US11840564B2 (en) | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| CA2988982A1 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| WO2016209956A1 (en) * | 2015-06-26 | 2016-12-29 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| KR20180054639A (ko) | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| WO2017044811A1 (en) | 2015-09-11 | 2017-03-16 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| TWI784917B (zh) | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗ｃｄ３雙特異性抗體及其用途 |
| SG10201912150TA (en) | 2015-10-06 | 2020-02-27 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| JP2018530574A (ja) | 2015-10-07 | 2018-10-18 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の加齢黄斑変性を治療する方法 |
| CN116003596A (zh) | 2015-10-29 | 2023-04-25 | 艾利妥 | 抗siglec-9抗体及其使用方法 |
| ES2941640T3 (es) | 2015-12-16 | 2023-05-24 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento |
| JP7339733B2 (ja) | 2016-01-14 | 2023-09-06 | ケモセントリックス，インコーポレイティド | Ｃ３腎症を処置する方法 |
| WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
| HRP20241557T1 (hr) | 2016-03-10 | 2025-05-23 | Acceleron Pharma Inc. | Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba |
| CA3018272A1 (en) | 2016-04-22 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 binding proteins and uses thereof |
| EP3463461A4 (en) | 2016-05-27 | 2020-05-20 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| KR102667023B1 (ko) | 2016-06-14 | 2024-05-21 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 및 이의 용도 |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| JP7096240B2 (ja) | 2016-10-19 | 2022-07-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 試料中の非結合ｃ５の定量化方法 |
| EP3551210A1 (en) | 2016-12-07 | 2019-10-16 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
| BR112019011769A2 (pt) * | 2016-12-16 | 2019-11-12 | Samsung Bioepis Co Ltd | composição de anticorpo anti-c5 aquosa estável |
| PL3577135T3 (pl) | 2017-01-31 | 2023-12-04 | Chugai Seiyaku Kabushiki Kaisha | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 |
| AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| US11359014B2 (en) | 2017-05-16 | 2022-06-14 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| JP7194698B2 (ja) | 2017-05-22 | 2022-12-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者においてタンパク質漏出性腸症を処置するための抗ｃ５抗体の投薬量および投与 |
| CA3102086A1 (en) | 2017-06-06 | 2018-12-13 | Relinia, Inc. | Single-chain tnf receptor 2 agonist fusion proteins |
| KR20230066126A (ko) | 2017-07-27 | 2023-05-12 | 알렉시온 파마슈티칼스, 인코포레이티드 | 고농도 항-c5 항체 제형 |
| CN111163767A (zh) | 2017-08-02 | 2020-05-15 | 艾其林医药公司 | 治疗阵发性睡眠性血红蛋白尿症的治疗方案 |
| AU2018310985A1 (en) | 2017-08-03 | 2019-11-07 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| MD3601358T2 (ro) | 2017-08-03 | 2023-10-31 | Alector Llc | Anticorpi anti-TREM2 și metode de utilizare a acestora |
| MX2020004284A (es) | 2017-10-26 | 2020-10-28 | Alexion Pharma Inc | Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua). |
| MX2020004933A (es) | 2017-11-14 | 2021-01-08 | Arcellx Inc | Polipéptidos que contienen dominios d y sus usos. |
| WO2019108456A1 (en) | 2017-12-01 | 2019-06-06 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| CN111683672A (zh) * | 2017-12-04 | 2020-09-18 | Ra制药公司 | 补体活性调节剂 |
| CN120571008A (zh) | 2017-12-13 | 2025-09-02 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
| US11440957B2 (en) | 2017-12-29 | 2022-09-13 | Alector Llc | Anti-TMEM106B antibodies and methods of use thereof |
| JP7268038B2 (ja) | 2018-01-31 | 2023-05-02 | アレクトル エルエルシー | 抗ｍｓ４ａ４ａ抗体及びその使用方法 |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| TW202448946A (zh) | 2018-05-25 | 2024-12-16 | 美商阿列克特有限責任公司 | 抗-sirpa 抗體及其使用方法 |
| ES2996257T3 (en) | 2018-05-31 | 2025-02-12 | Alexion Pharma Inc | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| US12460012B2 (en) | 2018-06-04 | 2025-11-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients |
| KR20210030341A (ko) | 2018-06-08 | 2021-03-17 | 알렉터 엘엘씨 | 항-Siglec-7 항체 및 그의 사용 방법 |
| CA3104295A1 (en) * | 2018-06-19 | 2019-12-26 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
| WO2020006266A1 (en) | 2018-06-28 | 2020-01-02 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| CN112384532B (zh) | 2018-06-29 | 2025-01-10 | 艾利妥 | 抗SIRP-β1抗体及其使用方法 |
| RS64034B1 (sr) | 2018-07-13 | 2023-04-28 | Alector Llc | Anti-sortilin antitela i načini njihove upotrebe |
| KR20210049106A (ko) | 2018-07-27 | 2021-05-04 | 알렉터 엘엘씨 | 항-siglec-5 항체 및 이의 사용 방법 |
| CR20210103A (es) | 2018-08-01 | 2021-03-22 | Chugai Pharmaceutical Co Ltd | Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5 |
| SG11202101552SA (en) | 2018-08-31 | 2021-03-30 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| IL280875B2 (en) | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| EP3847174A4 (en) | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS |
| JP2022502500A (ja) | 2018-09-25 | 2022-01-11 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ阻害剤の形態 |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| AU2019370295A1 (en) | 2018-10-30 | 2021-06-03 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| JP7471300B2 (ja) | 2018-12-17 | 2024-04-19 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体介在性疾患を治療するための的を絞った投与 |
| EP3941462A4 (en) | 2019-03-22 | 2023-04-05 | Achillion Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES |
| EP3980047B1 (en) | 2019-06-04 | 2024-02-14 | RA Pharmaceuticals, Inc. | Inflammatory disease treatment with complement inhibitors |
| KR102919581B1 (ko) | 2019-06-11 | 2026-01-30 | 알렉터 엘엘씨 | 치료요법에 사용하기 위한 항-소르틸린 항체 |
| WO2021019036A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
| EP4003408A1 (en) | 2019-07-31 | 2022-06-01 | F. Hoffmann-La Roche AG | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
| BR112022001733A2 (pt) | 2019-07-31 | 2022-06-28 | Alector Llc | Anticorpos anti-ms4a4a e métodos de uso dos mesmos |
| WO2021026160A1 (en) | 2019-08-05 | 2021-02-11 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis with eculizumab |
| CN115003699A (zh) | 2019-12-05 | 2022-09-02 | 艾利妥 | 抗trem2抗体的使用方法 |
| MX2022007156A (es) | 2019-12-12 | 2022-09-07 | Alector Llc | Metodos de uso de anticuerpos anti-cd33. |
| AU2020401319A1 (en) | 2019-12-13 | 2022-06-30 | Alector Llc | Anti-MerTK antibodies and methods of use thereof |
| US20230159637A1 (en) | 2020-02-24 | 2023-05-25 | Alector Llc | Methods of use of anti-trem2 antibodies |
| US20240294650A1 (en) | 2020-03-31 | 2024-09-05 | Alector Llc | Anti-mertk antibodies and methods of use thereof |
| AU2021247286A1 (en) | 2020-04-03 | 2022-10-20 | Alector Llc | Methods of use of anti-TREM2 antibodies |
| CN116406287A (zh) | 2020-04-16 | 2023-07-07 | 巴黎公共医疗救助机构 | 治疗由病毒引起的补体介导的障碍的方法 |
| CN115666578A (zh) | 2020-05-12 | 2023-01-31 | 阿雷克森制药公司 | 补体因子d抑制剂单独或结合抗c5抗体治疗阵发性睡眠性血红蛋白尿的用途 |
| WO2022120352A1 (en) | 2020-12-02 | 2022-06-09 | Alector Llc | Methods of use of anti-sortilin antibodies |
| JP2024512002A (ja) | 2021-03-18 | 2024-03-18 | アレクトル エルエルシー | 抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法 |
| JP2024511610A (ja) | 2021-03-23 | 2024-03-14 | アレクトル エルエルシー | コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体 |
| CA3220629A1 (en) | 2021-05-28 | 2022-12-01 | Tobin J. CAMMETT | Methods for detecting cm-tma biomarkers |
| WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| WO2022266221A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Monovalent anti-mertk antibodies and methods of use thereof |
| WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
| WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CN118765204A (zh) | 2022-02-23 | 2024-10-11 | 艾利妥 | 抗trem2抗体的使用方法 |
| CN119630428A (zh) | 2022-07-12 | 2025-03-14 | 西托姆克斯治疗公司 | Epcam免疫缀合物及其用途 |
| EP4561703A1 (en) | 2022-07-29 | 2025-06-04 | Alector LLC | Anti-gpnmb antibodies and methods of use thereof |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| WO2024148232A2 (en) | 2023-01-06 | 2024-07-11 | Alector Llc | Anti-il18 binding protein antibodies and methods of use thereof |
| AR133963A1 (es) | 2023-09-29 | 2025-11-19 | Trex Bio Inc | MOLÉCULAS DE FUSIÓN VARIANTE TNF-a |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5135916A (en) * | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE3924924A1 (de) | 1989-07-27 | 1991-02-07 | Goetze Otto | Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg |
| JPH06503344A (ja) | 1990-12-06 | 1994-04-14 | ティーセル サイエンシズ，インコーポレーテッド | 可溶性の補体受容体と、補体を抑制しかつ／または免疫活性を抑制する化合物との相乗組成物 |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| DE69531148T2 (de) | 1994-01-31 | 2004-04-29 | Trustees Of Boston University, Boston | Bibliotheken aus polyklonalen antikörpern |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| EP0777474B1 (en) | 1994-09-23 | 2005-12-21 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of inflammatory joint disease |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP1253946A2 (en) | 2000-02-10 | 2002-11-06 | Alexion Pharmaceuticals, Inc. | Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof |
| US6534058B2 (en) | 2000-10-10 | 2003-03-18 | Tanox, Inc. | Anti-C5 monoclonal antibodies |
| CA2436671C (en) * | 2000-12-05 | 2015-02-03 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| WO2003009803A2 (en) | 2001-07-26 | 2003-02-06 | Alexion Pharmaceuticals Inc. | Method of improving cognitive function |
| ES2283594T5 (es) | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| WO2003081206A2 (en) * | 2002-03-18 | 2003-10-02 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| WO2004019861A2 (en) | 2002-08-28 | 2004-03-11 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| PL216630B1 (pl) | 2002-10-17 | 2014-04-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| KR101001176B1 (ko) | 2002-12-16 | 2010-12-15 | 코닌클리케 필립스 일렉트로닉스 엔.브이. | 콘텐츠를 기록 및 재생하는 방법, 사용자 인터페이스 및 개인용 비디오 레코더 시스템 |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| JP2006516636A (ja) | 2003-01-30 | 2006-07-06 | メディミューン，インコーポレーテッド | 抗インテグリンαｖβ３抗体製剤及びその用途 |
| NO346070B1 (no) | 2003-02-10 | 2022-01-31 | Biogen Ma Inc | Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav. |
| HRP20050934B1 (hr) | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| JP2007525176A (ja) * | 2003-04-25 | 2007-09-06 | イミュネックス・コーポレーション | 組換えタンパク質発現の誘導剤 |
| CA2527878A1 (en) | 2003-05-30 | 2005-01-27 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| WO2004108158A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-cd3 antibody |
| US20050027166A1 (en) | 2003-06-17 | 2005-02-03 | Shinya Matsumoto | Endoscope system for fluorescent observation |
| AT412877B (de) | 2003-07-01 | 2005-08-25 | Miba Gleitlager Gmbh | Schichtwerkstoff |
| US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| DK1755659T3 (da) | 2004-03-24 | 2012-02-27 | Abbott Biotherapeutics Corp | Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation |
| DK1755674T3 (en) | 2004-05-14 | 2015-02-09 | Alexion Pharma Inc | PROLONGED SURVIVAL OF A allograft by inhibiting complement activity |
| DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| EP1771565B1 (en) | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
| EP1902320B1 (en) | 2005-05-20 | 2010-03-10 | Genentech, Inc. | Pretreatment of a biological sample from an autoimmune disease subject |
| WO2007002571A2 (en) | 2005-06-23 | 2007-01-04 | Alexion Pharmaceuticals, Inc. | Use of an anti c5 complement antibody to treat patients with sickle cell disease |
| EP1899477A4 (en) | 2005-07-01 | 2010-01-20 | Medimmune Inc | INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS |
| AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| CA2644020C (en) | 2006-03-02 | 2016-05-10 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| SI2359834T1 (sl) | 2006-03-15 | 2017-02-28 | Alexion Pharmaceuticals, Inc. | Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa |
| EP2013235A1 (en) | 2006-05-01 | 2009-01-14 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| US9388235B2 (en) | 2006-09-05 | 2016-07-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
-
2007
- 2007-03-15 SI SI200731886T patent/SI2359834T1/sl unknown
- 2007-03-15 EP EP16172335.8A patent/EP3124029A1/en not_active Ceased
- 2007-03-15 BR BR122017024057A patent/BR122017024057B8/pt active IP Right Grant
- 2007-03-15 EP EP16195355.9A patent/EP3167888B1/en active Active
- 2007-03-15 BR BRPI0708909A patent/BRPI0708909B8/pt active IP Right Grant
- 2007-03-15 CA CA3022097A patent/CA3022097C/en active Active
- 2007-03-15 PL PL11001632T patent/PL2359834T3/pl unknown
- 2007-03-15 ES ES16195355T patent/ES2965283T3/es active Active
- 2007-03-15 IL IL302157A patent/IL302157A/en unknown
- 2007-03-15 HU HUE16195355A patent/HUE066795T2/hu unknown
- 2007-03-15 EP EP11001632.6A patent/EP2359834B1/en not_active Revoked
- 2007-03-15 EP EP23198329.7A patent/EP4316465A3/en active Pending
- 2007-03-15 EP EP07753249A patent/EP2001490A1/en not_active Ceased
- 2007-03-15 PT PT110016326T patent/PT2359834T/pt unknown
- 2007-03-15 DK DK11001632.6T patent/DK2359834T5/en active
- 2007-03-15 KR KR1020087024657A patent/KR20080110800A/ko not_active Ceased
- 2007-03-15 CA CA2645810A patent/CA2645810C/en active Active
- 2007-03-15 AU AU2007225044A patent/AU2007225044C1/en active Active
- 2007-03-15 KR KR1020147008290A patent/KR20140057635A/ko not_active Ceased
- 2007-03-15 US US12/225,040 patent/US20090220508A1/en not_active Abandoned
- 2007-03-15 PL PL16195355.9T patent/PL3167888T3/pl unknown
- 2007-03-15 HU HUE11001632A patent/HUE030105T2/en unknown
- 2007-03-15 JP JP2009500498A patent/JP2009530299A/ja not_active Withdrawn
- 2007-03-15 MX MX2008011735A patent/MX340784B/es active IP Right Grant
- 2007-03-15 WO PCT/US2007/006606 patent/WO2007106585A1/en not_active Ceased
- 2007-03-15 ES ES11001632.6T patent/ES2612118T3/es active Active
-
2008
- 2008-09-11 IL IL194041A patent/IL194041A/en active IP Right Grant
- 2008-09-12 MX MX2022002589A patent/MX2022002589A/es unknown
-
2012
- 2012-03-22 US US13/426,973 patent/US20120237515A1/en not_active Abandoned
-
2013
- 2013-10-23 JP JP2013219882A patent/JP2014015484A/ja not_active Withdrawn
-
2015
- 2015-12-03 JP JP2015236260A patent/JP6224059B2/ja active Active
-
2016
- 2016-05-06 US US15/148,839 patent/US9718880B2/en active Active
- 2016-09-09 US US15/260,888 patent/US9725504B2/en active Active
- 2016-10-03 US US15/284,015 patent/US9732149B2/en active Active
-
2017
- 2017-02-20 JP JP2017028811A patent/JP2017082017A/ja not_active Withdrawn
- 2017-05-14 IL IL252260A patent/IL252260B/en active IP Right Grant
- 2017-07-05 US US15/642,096 patent/US10590189B2/en active Active
-
2018
- 2018-04-08 IL IL258548A patent/IL258548A/en unknown
- 2018-07-25 JP JP2018139327A patent/JP2018165277A/ja not_active Withdrawn
-
2019
- 2019-10-08 JP JP2019185225A patent/JP2020002176A/ja not_active Withdrawn
-
2020
- 2020-01-23 US US16/750,978 patent/US20200392216A1/en not_active Abandoned
- 2020-02-28 US US16/804,567 patent/US10703809B1/en active Active
-
2021
- 2021-02-17 JP JP2021023314A patent/JP2021073319A/ja not_active Withdrawn
-
2022
- 2022-12-28 JP JP2022211659A patent/JP2023026536A/ja not_active Withdrawn
-
2025
- 2025-05-30 JP JP2025091052A patent/JP2025120217A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016034978A5 (enExample) | ||
| CY1124675T1 (el) | Σταθερη καθορισμενης δοσης φαρμακευτικη συνθεση που περιλαμβανει μομεταζονη και ολοπαταδινη για ρινικη χορηγηση | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2012255026A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2016515522A5 (enExample) | ||
| JP2016539157A5 (enExample) | ||
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| JP2015057451A5 (enExample) | ||
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2016523260A5 (enExample) | ||
| JP2017537912A5 (enExample) | ||
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| JP2015516419A5 (enExample) | ||
| WO2016074641A8 (zh) | Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用 | |
| WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
| JP2014148552A5 (enExample) | ||
| EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη |